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ABSTRACT. 1,2-Hydroxypyridinones (1,2-HOPO) form very stable lanthanide complexes that may be 
useful as contrast agents for Magnetic Resonance Imaging (MRI). X-ray diffraction of single crystals 
established that the solid state structures of the Eu(III) and the previously reported [Inorg. Chem. 2004, 
43, 5452] Gd(III) complex are identical. The recently discovered sensitizing properties of 1,2-HOPO 
chelates for Eu(III) luminescence allow direct measurement of the number if water molecules in the 
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metal complex. Fluorescence measurements of the Eu(III) complex corroborate that in solution two 
water molecules coordinate the lanthanide (q = 2) as proposed from the analysis of NMRD profiles. In 
addition, fluorescence measurements have verified the anion binding interactions of lanthanide TREN-
1,2-HOPO complexes in solution, studied by relaxivity, revealing only very weak oxalate binding 
(KA = 82.7 ± 6.5 M
-1). Solution thermodynamic studies of the metal complex and free ligand  have been 
carried out using potentiometry, spectrophotometry and fluorescence spectroscopy. The metal ion 
selectivity of TREN-1,2-HOPO supports the feasibility of using 1,2-HOPO ligands for selective 
lanthanide binding [pGd = 19.3 (2); pZn = 15.2 (2), pCa = 8.8 (3)]. 
KEYWORDS. 1,2-Hydroxypyridonate, Gadolinium, Europium, MRI, Fluorescence, Chelate stability, 
Selectivity, Solution thermodynamics. 
 
Introduction 
High chelate stability is essential for lanthanide complexes in medicine because lanthanide ions have 
known toxicity via their interaction with Ca(II) binding sites.2 Additionally, the application of weak 
Gd(III) chelators as MRI contrast agent (MRI-CA) can cause nephrogenic systemic fibrosis in patients 
with low kidney activity.3 To date gadolinium based contrast agents for magnetic resonance imaging 
(MRI-CA) used clinically rely on conveniently available aminocarboxylate chelates derived from 
DTPA and macrocyclic DOTA.4 However, the weak Gd(III) nitrogen bond does not significantly 
contribute to chelate stability in these compounds. Thus, only octadentate ligands provide sufficient 
chelate stability, which limits the number of coordinated water molecules to one (q = 1). The resulting 
limit in relaxivity can be circumvented by utilizing the known oxophilicity of lanthanides. Purely 
oxygen donor ligands such as hydroxypyridinone (HOPO, Chart 1) and terephthalamide (TAM) 
chelates allow two5 or three6 coordinated water molecules (q = 2 or 3) at the metal center without 
destroying chelate stability, and have been established as candidates for high relaxivity next generation 
contrast agents. These ligands combine enhanced relaxivity and high stability – a combination 
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considered impossible for small molecular weight MRI-CA based on aminocarboxylate ligands.7 The 
further development of mixed 3,2-HOPO-TAM chelates follows the current trend of improving 
relaxometric properties of MRI-CA by formation of polymers8, dendrimers9 or supramolecular 
compounds.10 The feasibility of applying such 3,2-HOPO chelates as MRI-CA has been proven 
successfully in vivo.11 
 
It has been one of the very few disfavored features of 3,2-HOPO that the solution structure of its 
lanthanide complexes cannot be elucidated by other means than relaxometry. Methods such as Dy(III) 
induced paramagnetic shift in 17O-NMR spectroscopy,12 or fluorescence spectroscopy of parent Eu(III) 
or Tb(III) chelates13 have been investigated without much success. As such, information about the 
solution structure including the hydration number q for 3,2-HOPO and TAM chelates has been inferred 
only by relaxometry based on reasonable assumptions about the values of several parameters and, 
whenever possible, on the comparison of 1H and 17O NMR relaxation data. The recent discovery of the 
excellent luminescence sensitizing properties of 6-carboxylamide-1,2-hydroxypyridonates (1,2-HOPO) 
for Eu(III)14 allows the correlation of relaxometric data with fluorescence spectroscopy for 1,2-HOPO 
compounds. Contrary to several well studied 3,2-HOPO chelates, only TREN-1,2-HOPO15 and TACN-
1,2-HOPO6 have been described as 1,2-HOPO chelates for MRI contrast agents. Comparison of the 
solid state structure and NMRD profile of Gd-TREN-1,2-HOPO with Gd-TREN-3,2-HOPO led to the 
conclusion that these complexes behave very similarly in solution.15 
 
Thus, 1,2-HOPO can be used as a fluorescent tool to elucidate solution structure of HOPO chelates by 
fluorescence spectroscopy in addition to relaxometry and solution thermodynamics. The following 
contribution presents details on solution stability and structure of the Eu(III), Gd(III) and Zn(II) 
complexes of TREN-1,2-HOPO. For the first time, fluorescence spectroscopy of a TREN-HOPO 
chelate as the Eu(III) complex are used to support solution structure assignments based on relaxivity 
measurements for the same ligand with Gd(III). This comparative study of relaxometric data of the 
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Gd(III)-TREN-1,2-HOPO complex and luminescence data of the isostructural Eu(III) complex was also 
applied for determining binding affinities of bioavailable and synthetically interesting anions for the 
Eu(III) and Gd(III) complexes of TREN-1,2-HOPO and to assign the structure of ternary complexes in 
solution. In addition, solution thermodynamic stability was assessed for an estimate of potential toxicity 
of TREN-1,2-HOPO chelates. 
 
Experimental details  
 
General 
All chemicals were used as received from Aldrich unless otherwise noted.  TREN-1,2-HOPO15 
and 3-benzoxy-4-carboxy-2-pyridone (3,2-HOPO(Bn) acid)5 were synthesized as previously reported.  
1H and 13C NMR spectra were obtained on Bruker AVQ-400 spectrometers and are reported in ppm.  
Mass spectra and elemental (CHN) analyses were performed at the Elemental Analysis Facility, College 
of Chemistry, UC Berkeley.  Unless specified, solvents were removed by rotary evaporation. 
Synthesis  
3-Benzyloxy-4-methylcarbamido-1-methyl-2-pyridone 
3-Benzyloxy-4-carboxy-1-methyl-2-pyridone (2.56 g, 10 mmol) was dissolved in toluene (10 mL). 
Oxalylchloride (3.81 g, 30 mmol) and three drops of DMF were added. Volatiles were removed after 
gas evolution ceased (~ 1 hr) and the remaining solid was dissolved in dry THF (50 mL). Methylamine 
(40 % in water; 50 mL) was diluted with THF (50 mL), cooled on an ice bath and the solution of 3-
benzyloxy-4-carboxychloro-1-methyl-2-pyridone was added. The reaction mixture was stirred on an ice 
bath for 4 hr. and dichloromethane (250 mL) was added. The reaction mixture was washed with 1 M 
HCl (3 x 100 mL), 1 M KOH (3 x 100 mL) and water (1 x 50 mL) and dried over Na2SO4. Volatiles 
were removed under reduced pressure and a yellowish solid remained. Yield: 2.34 g (8.59 mmol, 86 %) 
1H NMR (CDCl3, 400.132 MHz) δ = 7.89 (s, 1 H, amide NH), 7.43-7.33 (m, 5 H, Bn-CH), 7.13 (d, 1 H, 
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6-CHHOPO, 
3JHH = 7.2 Hz), 6.78 (d, 1 H, 6-CHHOPO, 
3JHH = 7.2 Hz), 5.54 (s, 2 H, OCH2Ph), 3.59 (s, 3 H, 
NHOPOCH3), 2.78 (d, 3 H, . 4-CONHCH3, 
2JHH vic= 5.2 Hz). 
13C NMR (CDCl3, 100.623 MHz) δ = 163.8 
(CONH), 159.7 (CONH), 146.4, 136.2, 132.2, 130.8 (ipso-C-Bn), 129.1 (Ph-CH), 128.9 (Ph-CH), 128.8 
(Ph-CH), 128.4, 126.9, 104.9 (5-CHHOPO), 65.1 (OCH2Ph), 37.7 (1-NCH3), 26.3 (4-CONHCH3). ESI-
MS (MeOH) m/z = 567.2 (95 %, [2M+Na]+), 295.2 (100 %, [MNa]+). 
 
3-Hydroxy-4-methylcarbamido-1-methyl-2-pyridone 
3-Benzyloxy-4-methylcarbamido-1-methyl-2-pyridone (2.34 g, 8.59 mmol) was dissolved in acetic acid 
(6 mL). Hydrochloric acid (6 mL) was added and the solution was stirred for 18 hrs. Solvents were 
removed under reduced pressure. Water (100 mL) was added to the remaining yellowish suspension. 
The mixture was extracted with methylene chloride (2x 100 mL) and the remaining colorless 
suspension was filtered. Concentration of the filtrate allowed the collection of a second crop of the title 
compound as colorless needles. Combined yield: 658 mg (3.61 mmol, 42 %). Melting point: 201°C. fw 
= 182.18 g/mol. Anal. for C8H10N2O3 calcd. (found): C 52.74 (52.37), H 5.53 (5.59), 15.38 (14.99). 
1H 
NMR (d6-DMSO, 400.132 MHz) δ = 11.7 (s br, 1 H, OH), 8.40 (d, 1 H, amide NH), 7.15 (d, 1 H, 6-
CHHOPO, 
3JHH = 7.2 Hz), 6.46 (d, 1 H, 6-CHHOPO, 
3JHH = 7.2 Hz), 3.43 (s, 3 H, NHOPOCH3), 2.77 (d, 3 H, . 
4-CONHCH3, 
2JHH vic= 5.2 Hz). 
13C NMR (d6-DMSO, 100.623 MHz) δ = 166.6 (CONH), 158.4 
(CONH), 148.3, 128.1, 117.3, 102.7 (5-CHHOPO), 37.2 (1-NCH3), 26.5 (4-CONHCH3). FAB-MS (NBA) 
m/z = 183 (100 %, [MH]+), 152 (43 %, [MH-CH3N]
+), 136 (18 %, [MH-CH3NO]
+). 
[Eu(TREN-1,2-HOPO)(H2O)]2:  
To a solution of TREN-1,2-HOPO (61 mg, 0.10 mmol) in methanol (10 mL), was added a solution of 
europium chloride hexahydrate (36 mg, 0.1 mmol) in methanol (10 mL) while stirring. The clear 
solution became turbid after 2 drops of dry pyridine were added. The mixture was refluxed overnight 
under nitrogen, during which time the complex deposited as a white powder. The precipitate was 
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collected, rinsed with cold methanol, and dried to give the title complex (63 mg, 89 %) as a white 
solid.  Anal. for EuC24H24N7O9·H2O,  Calcd. (Found): C, 39.79 (40.01); H, 3.62 (3.47); N, 13.53 
(13.26). 
Crystals of [Eu(C24H24N7O9·C3H7NO)]2 x 0.5 C3H7NO x 0.5 C4H10O suitable for X-ray diffraction were 
obtained from vapor diffusion of diethyl ether into a DMF solution (Table S1). 
  
Solution Thermodynamics 
The experimental protocols and equipment used have been previously described.16  To determine the 
protonation constants of the free ligand, approximately 13.5 to 25.2 mg of ligand was dissolved in 25 or 
50 mL of a 0.1 M aqueous solution of KCl in a titration vessel (ligand concentration ~0.4 to 0.7 mM).  
Protonation constants of TREN-1,2-HOPO were determined by potentiometric (pH vs total proton 
concentration) titrations using Hyperquad17 for data refinement. Each protonation constant 
determination is the result of at least three experiments (where each experiment consists of two 
titrations, the first one titrated with acid, followed by a reverse titration with base). The equilibration 
time between additions of titrant was 90 seconds for ligand titrations. Spectrophotometric titrations of 
~40 µmol solutions of TREN-1,2-HOPO were fitted using pHAb18 for computation. Molar absorbances 
of the species L3-, LH2-, LH2
-, LH3, and LH4
+ were determined (Figure S3) and interpreted to assign 
protonation sites. The smallest change in absorption between two species results from the protonation at 
the amine nitrogen atom, which is not directly adjacent to the 1,2-HOPO chromophores monitored in 
the wavelength region between 280 and 380 nm. 
1H (Table S6; Figure 4) and 13C NMR (Table S7; Figure S3) titrations were performed on a solution 
of TREN-1,2-HOPO (88.34 mM) in 4 mL D2O. The pD of this solution was also monitored and varied 
by stepwise addition of KOD/D2O (30 %; ~1–10 µL). The corresponding pH was calculated by the 
relation pD = 1.044 pH – 0.32.19 A small amount of methanol was used as standard (δ1H = 3.32 ppm; 
δ13C = 49.50 ppm).20 
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The general procedure used to determine the conditional stability constants pGd, pZn or pCa of a 
TREN-1,2-HOPO complex was competition batch titration adapted from a previous report.21 Varying 
volumes of a standardized DTPA stock solution were added to solutions containing constant ligand, 
metal, buffer [0.01 M of either MES (= 2-(N-morpholine)-ethanesulfonic acid) pH 6.1; HEPES (= 4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid) or TRIS (= 2-amino-2-hydroxymethyl-propane-1,3-
diol) for pH 7.4] and electrolyte (0.1 M KCl) concentrations. If necessary, the pH of the solutions was 
adjusted with concentrated HCl and/or KOH and the solutions were diluted to identical volumes in 
buffered electrolyte solution. The concentrations of TREN-1,2-HOPO relative to DTPA ranged from 
10:1 to 1:1000. After equilibrating for 24 h to ensure thermodynamic equilibrium, concentrations of free 
and complexed TREN-1,2-HOPO were determined from the absorption spectra, using the wavelength 
range from 320 – 360 nm (pGd; Figures 5 and S7), 320 – 350 nm (pZn; Figures 7 and S8), 320 – 
350 nm (pCa; Figure S9) and the spectra of free and fully complexed TREN-1,2-HOPO as references. 
 
Photophysical Measurements 
UV-Visible absorption spectra were recorded on a Varian Cary 300 double beam absorption 
spectrometer using quartz cells of 1.00 cm path length. Emission spectra were acquired on a HORIBA 
Jobin Yvon IBH FluoroLog-3 spectrofluorimeter, equipped with 3 slit double grating excitation & 
emission monochromators (2.1 nm/mm dispersion, 1200 grooves/mm). Spectra were reference 
corrected for both the excitation light source variation (lamp and grating) and the emission spectral 
response (detector and grating).  
Luminescence lifetimes were determined on a HORIBA Jobin Yvon IBH FluoroLog-3 
spectrofluorimeter, adapted for time-correlated single photon counting (TCSPC) and multichannel 
scaling (MCS) measurements. A sub-microsecond Xenon flashlamp (Jobin Yvon, 5000XeF) was used 
as the light source, with an input pulse energy (100 nF discharge capacitance) of ca. 50 mJ, yielding an 
optical pulse duration of less than 300 ns at FWHM. Spectral selection was achieved by passage 
through a double grating excitation monochromator (2.1 nm/mm dispersion, 1200 grooves/mm). 
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Emission was monitored perpendicular to the excitation pulse, again with spectral selection achieved by 
passage through a double grating excitation monochromator (2.1 nm/mm dispersion, 1200 
grooves/mm). A thermoelectrically cooled single photon detection module (HORIBA Jobin Yvon IBH, 
TBX-04-D) incorporating fast rise time PMT, wide bandwidth pre-amplifier and picosecond constant 
fraction discriminator was used as the detector. Signals were acquired using an IBH DataStation Hub 
photon counting module and data analysis was performed using the commercially available DAS 6 
decay analysis software package from HORIBA Jobin Yvon IBH. Goodness of fit was assessed by 
minimizing the reduced chi squared function, χ2, and a visual inspection of the weighted residuals. Each 
trace contained 10,000 points and the reported lifetime values result from three independent 
measurements. Typical sample concentrations for both absorption and fluorescence measurements were 
ca. 10-5-10-6 M and 1.0 cm cells in quartz suprasil or equivalent were used for all measurements. An 
example of a typical lifetime data trace and the corresponding best fit is shown in Figure S1. 
 
Relaxometric Measurements 
The water proton 1/T1 longitudinal relaxation rates (20 MHz, 25°C) were measured on a Stelar 
Spinmaster Spectrometer (Mede, Pv, Italy) on 30-45 μM aqueous solutions of the complexes. For the T1 
determinations the standard inversion-recovery method was used with typical 90° pulse width of 3.5 μs, 
16 experiments of 4 scans. The reproducibility of the T1 data was estimated to be ±1%. The temperature 
was controlled with a Stelar VTC-91 air-flow heater equipped with a copper-constantan thermocouple 
(uncertainty of 0.1±°C). In a typical titration experiment several (5-8) aqueous solutions at pH = 6.0 of 
the paramagnetic complex were prepared containing different concentrations of the anionic species (0-
0.04 M) and the water proton relaxation rate of each solution was measured at 25°C. The starting pH 
was adjusted by either HCl or KOH. Moreover, the pH of the solutions was controlled before and after 
the measurement. 
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Results and Discussion 
 
Solid State Structure 
The Eu(III) complex of TREN-1,2-HOPO (Figure 1) is isostructural with the Gd(III) complex. Both 
complexes crystallize in the monoclinic space group P2/n in dinuclear units, linked via an amide 
carbonyl oxygen atom and the lanthanide of the adjacent complex. Each ligand coordinates one metal 
center in a hexadentate fashion with a single DMF molecule completing the coordination sphere of the 
metal to eight (CN = 8). Distances for Ln-O bonds vary only to a very small degree reflecting the 
lanthanide contraction. Also the geometry around Gd(III) and Eu(III) atoms is identical as determined 
by the shape measure S22 for eight coordinate metal centers (Table S2) according to Kepert.23 The 
coordination geometry is described best by C2v symmetry corresponding to a bicapped trigonal prism. 
 
Solution Structure  
In aqueous solution, the amide oxygen atoms of DMF and the adjacent ligand are replaced with two 
fast exchanging water molecules (q = 2) as suggested by the NMRD profiles.15 For the first time, the 
number of coordinated water molecules q of a TREN-HOPO chelate could also be confirmed by 
luminescence spectroscopy of its parent Eu(III) complex. The luminescence quenching of coordinated 
water molecules can be used to determine q directly.13 Luminescence decaytimes of the Eu-
TREN-1,2-HOPO complex were found to be monoexponential at pH ~ 6 in aqueous solution and in 
D2O, with lifetimes of 222 µsec and 372 µsec, respectively (Figure S1). Utilizing the improved 
Horrocks relationship given by Parker24 gave an estimate of q = 1.9, which confirms the results obtained 
for the Gd(III) complex via relaxivity. 
 
For Eu(III), the 5D0 → 7FJ transitions are amenable to structural interpretation since, depending on the 
symmetry, crystal field splitting yields a maximum of 2J + 1 sublevels. Hence, emission spectra of the 
complex will reflect the symmetry of its immediate surroundings,25 and a complete analysis of crystal 
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field splitting parameters for the Eu(III) ion under various symmetry conditions using the principles of 
group theory has been detailed in the literature (Table S3).26  
 
Given the determination of an overall eight coordinate (q = 2) complex, a closer analysis of the 
emission spectra, in particular for the 5D0 → 7FJ (J = 0, 1) transitions, reveals insight into the solution 
behavior of the Eu(III) complex (Figure 2). The strength of the intensity of the J = 0 band at ca. 
17,300 cm-1 is comparable to J = 1 bands, which suggests this transition is symmetry allowed, implying 
C2v symmetry. Further analysis for the J = 1 region (ca. 16,700 cm
-1 to 17, 100 cm-1) confirms this 
assignment since only under C2v symmetry are three J = 1 bands expected, as clearly observed in the 
spectral deconvolution. Hence, the site symmetry C2v observed by X-ray crystallography for the TREN 
derivative is maintained in solution. 
 
Ligand Protonation 
Ligand protonation constants were determined by potentiometry in 0.1 M KCl (Table 1). 
Spectrophotometric and NMR titrations confirm these pKa values (Table S5). At physiological pH the 
ligand is almost completely deprotonated and available for metal complexation (Figure S2). The 
protonation sites have been assigned based on the molar absorbances of the species fitting 
spectrophotometric titrations (Figure 3). The very similar absorbances of the two most basic species 
(HL2- and L3-) indicate that the most basic protonation constant pKa 7.16 (1) should be assigned to the 
tertiary amine, since this protonation site is not directly linked to the 1,2-HOPO chromophores 
monitored between 260 and 400 nm. This assignment is supported by 1H and 13C NMR titrations 
(Figures 4 and S3, Tables S4–S6). In addition, assignment of resonances in 1H and 13C NMR spectra 
based on two dimensional HMBC and HMQC (Figures S4–6) spectra gave insight into molecular 
processes involved with protonation. While only minor shifts are observed for the aromatic proton 
resonances, the signals for 1´-CH2 and 5-CH (Chart 2) are shifting significantly between pH 5.3 and 7.7. 
The influence of deprotonation of the tertiary amine on the 1´-CH2 protons is clear, however, the reason 
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for the change in 5-CH resonance indicates that the structure of the molecule changes significantly. A 
careful analysis of shifts in proton and carbon resonances corroborates the hypothesis that the molecular 
solution structure of TREN-1,2-HOPO changes upon deprotonation by 180° rearrangement around the 
bond between 2´-CH2 and the amide nitrogen (Scheme 1) to maximize stabilizing hydrogen bond 
interactions. 
 
The average of the three pKa values associated with 1,2-HOPO hydroxylgroups (pKa av = 4.52) is 
slightly more acidic than expected based on similar compounds such as propyl-1,2-HOPO (pKa  = 
4.92).27 Also in contrast to 1-Me-3,2-HOPO-TREN (pKa = 4.97) or the model compound TREN-
MeSAM (pKa = 6.01 (7))
28 the tertiary amine is more basic (pKa = 7.16 (1)). This can be rationalized by 
the hydrogen bond network, which links the four protonation sites via the amide hydrogen atoms and by 
electrostatic interaction caused by additional charges in TREN-1,2-HOPO. Protonation constants of 
model compounds Pr-3,2-HOPO (pKa = 6.12 (1)), Pr-1,2-HOPO (pKa = 4.92 (2)) and TREN-MeSAM 
(pKa = 6.01 (7)) support this assignment and illustrate the difference in the acidity of protonation sites 
of TREN-1,2-HOPO and TREN-3,2-HOPO. The interaction between the protonation sites amplifies 
effects resulting from deprotonation at adjacent sites, which change the pKa values. Thus, the pKa 
values in both TREN-3,2-HOPO and TREN-1,2-HOPO are lower for the more acidic and higher for the 
more basic moieties compared to reference compounds. The “undisturbed” tertiary amine has a pKa 
6.01 (7), which is more acidic than the 3,2-HOPO hydroxyl group, but more basic than the 1,2-HOPO 
hydroxyl group. This reverse assignment of protonation sites of TREN-1,2-HOPO (amine most basic 
pKa = 7.16) compared to TREN-3,2-HOPO (amine most acidic pKa = 4.97) is important for explaining 
differences in the lanthanide chelation and protonation behavior (vide infra). 
 
Stability of the Gadolinium Complex 
The low solubility of [Gd(TREN-1,2-HOPO)(H2O)2] (csat = 85 µM) prevents potentiometric titrations 
for stability assessment and automated spectrophotometric titration experiments were prevented by slow 
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protonation kinetics. Hysteresis behavior for the titration from acidic to basic pH and reverse was 
observed between pH 4 and 8. Notably, no protonation is observed above pH 8 since the tertiary amine 
represents the most basic function in the ligand. We assign the tertiary amine of the TREN scaffold as 
also the most basic function in this ligand. The observed slow equilibration we attribute to slowed 
rotation in the ligand around the CC bond between carbamide and aryl ring, most likely occurring upon 
change of the protonation state at the tertiary amine. It has been shown previously for similar ligands 
that the resulting hydrogen bond network for the protonated ligand and the metal complex results in 
different conformations.29 The fact that this kinetic hindrance is not observed for TREN-3,2-HOPO and 
similar more basic ligands corroborates the assumption that the amine protonation is crucial for this 
behavior. 
 
Slow kinetics were circumvented by using batch titration techniques, which allow for long 
equilibration times typically between one and three days. Competition batch titrations versus DTPA 
were employed to determine the conditional stability constants at pH 6.1 and 7.4 (Figure 5). From these 
data and the protonation constants of the ligand, the Gd(III) complex formation constant logβ110 18.5 (2) 
was calculated. This number and the protonation of the complex at pKa 5.0 (2) and 3.5 (5) are reflected 
in changes of fluorescence intensity versus pH of the Eu(III) complex (Figure S10) and relaxivity versus 
pH of the Gd(III) complex (Figure S11). In the alkaline region TREN-1,2-HOPO competes with the 
formation of europium hydroxide.30 The competition of oxide formation at high pH is accurately 
modeled using logβ110 18.0 (5) and published europium oxide formation constants. In addition the pH 
profile of relaxivity suggests that Gd(III) remains coordinated to very acidic pH values, around 1. This 
is in agreement with the suggested stability and the acidic nature of TREN-1,2-HOPO. Consequently, a 
non- or only very weakly luminescent species is formed upon first complex protonation. The increase in 
relaxivity from pH 4 to 2 is caused by partial hydrolysis of one ligand arm from a doubly protonated 
complex. While the site of the first complex protonation is attributed to the scaffold amine, which is the 
most basic function in the complex, the second protonation removes one of the 1,2-HOPO groups 
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leaving space for two additional water molecules. The increase in relaxivity from 9.5 to 17 mM-1s-1 
reflects this doubling of water coordination sites. 
 
The pGd7.4 19.3 (2) of TREN-1,2-HOPO is remarkably high considering the acidity of this ligand. A 
comparison of conditional stability constants pGd of TREN-3,2-HOPO, DTPA and TREN-1,2-HOPO 
versus pH demonstrates the advantage of TREN-1,2-HOPO (Figure 6). pGd reaches an optimum value 
at pH values at which ligand deprotonation no longer plays a role in the complexation equilibrium. 
Thus, for basic ligands such as DTPA or TREN-3,2-HOPO, deprotonation still limits the conditional 
stability constant pGd at pH 7.4 compared to logβ. By contrast, the more acidic TREN-1,2-HOPO 
reaches the “plateau” resulting from complete ligand deprotonation around physiological pH. 
Importantly, for application in MRI pH values above 7.4 play only a minor role. In contrast, acidotic 
patients with renal failure undergoing imaging have been reported to acquire symptoms of Gd(III) 
poisoning.31 A more acidic ligand such as TREN-1,2-HOPO clearly provides increased stability in the 
region between pH 1 and 7. 
 
Selectivity for Gd(III) versus Zn(II) and Ca(II) 
The toxicity of a MRI-CA does not only correlate with its thermodynamic complex stability, but also 
with metal binding selectivity of the ligand. Thus, the high gadolinium complex stability of a TREN-
1,2-HOPO needs to be completed by either very slow kinetics for metal exchange or preferably by 
maximized thermodynamic selectivity for Gd(III) over endogenous metals to prevent Gd(III) release in 
vivo. Zn(II) and Ca(II) are the most abundant metals in this respect, since the concentrations of 
uncomplexed Zn(II) (10-15 µM) and Ca(II) (0.4 – 2.5 mM) in serum are sufficient for release of lethal 
amounts of Gd(III) (~20 µM).1 The selectivity of TREN-1,2-HOPO for Gd(III) over Zn(II) and Ca(II) 
was determined by comparing the conditional stability constants pGd and pZn or pCa with those for the 
benchmark compound DTPA (pGd-pZn = 4.2; pGd-pCa = 11.7). 
 
 14 
Competition batch titrations against DTPA were employed to obtain complex stabilities for Zn(II)-
TREN-1,2-HOPO (Table 1, Figure 7). The competition experiments were performed at pH 6.1 and 7.4. 
Contrary to the Gd(III) chelate, no protonation occurs between pH 4.5 and 9. From these competition 
experiments pZn 15.2 (2) and logβ110 14.4 (1) were calculated. The Zn(II) binding of TREN-1,2-HOPO 
is relatively strong compared to bidentate 1,2-hydroxypyridinone, which forms a quaternary complex 
ZnL3 with logβ130 11.99.32 This increase in stability for TREN-1,2-HOPO may be attributed to 
involvement of the amine nitrogen atom in binding Zn(II), which also might account for the lack of 
observed amine protonation. The selectivity of TREN-1,2-HOPO for Gd(III) chelation over Zn(II) 
measured by the difference in conditional stability constants pGd-pZn 4.1 is sufficient compared to 
DTPA with pGd-pZn 4.2. 
 
Competition batch titrations of TREN-1,2-HOPO versus DTPA for Ca(II) resulted in pCa7.4 8.8 (3) 
(Figure S9). While more stable than Ca-DTPA, this low stability allows formation of Ca-TREN-1,2-
HOPO only above pH 4 in the presence of physiological amounts of Ca(II) (2.5 mM). The selectivity of 
TREN-1,2-HOPO versus Ca(II)  pCa-pGd 10.5 is excellent. 
 
3,2-HOPO ligands that form anionic and cationic Gd(III)chelates are highly selective for Gd(III) over 
Ca(II) and Zn(II) with ΔpM (Gd-Zn) between 6 and 8.33 Comparing basic 3,2-HOPO with acidic 1,2-
HOPO ligands, Zn(II) binding increases for more acidic ligands, while Gd(III) binding decreases for 
such ligands. Thus, for the design of highly selective and acid resistant MRI-CA, mixed ligands of 
acidic 1,2-HOPO and more basic 3,2-HOPO groups are suggested. Alternately, the number of acidic 
chelate groups could be raised to four resulting in an octadentate ligand with preferential binding of 
lanthanides.1 
 
Anion Affinity 
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Anion binding at the water coordination site reduces the efficiency of a MRI-CA by replacing these 
water molecules. For aminocarboxylate ligands, anion binding has been studied with a chiral 
macrocycle by luminescence spectroscopy of the Eu(III) complex, relaxometry of Gd(III) chelates, and 
NMR spectroscopy of Yb(III) complexes. In addition solid state crystal structures of ternary complexes 
were obtained to correlate solid and proposed solution structures.34 Binding constants of phosphate and 
oxalate are relatively low for DOTA and DTPA, but cationic complexes of DO3A amide derivatives 
(q = 2) can efficiently bind bidentate carboxylates such as citrate or malonate.35 Unlike these cationic 
chelates, neutral 3,2-HOPO complexes with q = 2 do not or only weakly bind biorelevant anions. Also a 
cationic and an anionic bis-3,2-HOPO-TAM chelate show smaller association constants with phosphate 
and oxalate than the commercial, q = 1 chelates Gd(DOTA) or Gd(DTPA).33 
 
The affinity of Ln-TREN-1,2-HOPO towards several anions was evaluated by relaxometry of the 
Gd(III) complex and luminescence spectrosocopy of the Eu(III) complex (Table 2). Endogenous anions 
like phosphate, carbonate, acetate, or malonate do not interact with both complexes (Figure 8). A weak 
interaction with oxalate was detected by decreasing relaxation rate (Figure 9) and increasing 
luminescence intensity. For complete formation of the ternary complex 1500 equivalents of oxalate are 
required, which corresponds to a very small binding constant of Ka 82.7 ± 6.5 M
-1 for the Gd(III) 
complex and 96 M-1 for the Eu(III) complex. 
 
Ascorbate and catecholate decrease the luminescence intensity of the Eu(III) complex, but no 
interaction was observed by relaxometry indicating the mechanism for luminescence quenching of the 
Eu(III) complex does not involve coordination at the metal center. It is possible the ligand triplet state 
may be quenched by catechol or ascorbate, or alternately, the excited Eu(III) may be partially reduced 
to Eu(II), which is too high in energy for sensitization by TREN-1,2-HOPO. 
 
 16 
It was also noted that the addition of up to 1000 equivalents of fluoride did not replace water. The 
only strong binding interaction was observed for a bidentate 3,2-HOPO anion (Figure 9). The binding 
constant is within the expected value around 3100 M-1 (logKa 3.5). This observation corroborates the 
assumption that only monoanionic and bidentate ligands would form strong ternary complexes with Eu-
TREN-1,2-HOPO. The 3,2-HOPO anion binds 1.5 order of magnitude stronger than oxalate, with 
saturation already below 20 equivalents while other bidentate ligands like catechol or maltol do not 
bind. 
 
Solution Structure of Ternary Complexes 
The change of relaxation rates between Gd-TREN-1,2-HOPO and the ternary adducts suggests that 
the coordination number increases from 8 to 9 upon binding of bidentate 3,2-HOPO or oxalate (Figure 
10). Indeed, the calculated relaxivities r1p (20 MHz, 25°C) of the ternary complexes (Table 2) are 
5.5±0.2 and 5.2±0.2 mM-1 s-1. These are typical values for q = 1 complexes. Pure outer sphere 
complexes (q = 0) would be characterized by relaxivity values of ca. 2.5-3.0 mM-1 s-1 under identical 
experimental conditions. 
 
Titrations of the Eu(III) complex with oxalate were monitored by variation of luminescence decay 
lifetimes which rise from 220 µs to 332 µs upon addition of 1500 equivalents of potassium oxalate. 
Under these conditions the ternary complex is the dominant species, which is also recognized by 
slight changes in the emission spectrum. Lifetime measurements clearly indicated the new species has 
one coordinated water (q = 0.8).24 The fact that ligands with one carboxylate group do not coordinate 
under these experimental conditions corroborates that oxalate functions as a bidentate ligand 
replacing only one water molecule. Such behavior was observed earlier in the oxalate binding of a 
tren substituted bis-3,2,-HOPO-TAM-TREN complex, which was interpreted as shifting the 
equilibrium from 8 and 9 coordinate complexes upon addition of oxalate.33 The emission spectrum of 
a 10 µM Eu-TREN-1,2-HOPO solution with 1500 equivalents oxalate differs slightly from the one of 
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a pure Eu-TREN-1,2-HOPO solution. Symmetry analysis of the J = 0 and 1 bands (Figure 10) for a 
nine-coordinate Eu(III) center suggests that the coordination geometry is a subgroup of C4v, since 
otherwise the J = 0 band would be absent (Table S3). Fitting the J = 1 band with three equally broad 
and intense Voigt functions (A and 2B) provides better a result than with two Voigt functions of  a 2:1 
intensity ratio (A and E). Thus the coordination geometry at the metal center can be assigned to C2, a 
subgroup of C4V. 
 
Conclusion 
The X-ray structures of [Eu(TREN-1,2-HOPO)(H2O)2] and [Gd(TREN-1,2-HOPO)(H2O)2] are 
isostructural with identical coordination geometries at the metal centers. This allows the direct 
comparison of relaxometric measurements of the Gd(III) complex with the emission spectra of the 
Eu(III) complex. The protonation constants of TREN-1,2-HOPO were determined and assigned 
revealing a change in the order of protonation sites, which also influences the sequence of protonating 
the Gd(III) complex. The high Gd(III) binding constant of TREN-1,2-HOPO is matched by sufficient 
selectivity versus Zn(II) and excellent selectivity versus Ca(II) binding. In addition, the greater ligand 
acidity provides enhanced stability under slightly acidic conditions. The expectation of low toxicity 
Gd(III)-TREN-1,2-HOPO is completed by low anion interactions. A detailed study on the ternary 
oxalate adduct reveals insights into solution structure and demonstrates the comparable energies of the 
8- and 9 coordinate Gd(III), which is an essential feature for the advantageous relaxometric properties 
of the MRI contrast agents based on HOPO chelates. 
Despite the differences, 1,2-HOPO chelates overall serve as good models for non-luminescent 3,2-
HOPO chelates. The higher acidity of the 1,2-HOPO chelate group compared to 3,2-HOPO facilitates 
handling and analysis since the complexes are less sensitive to acid hydrolysis. The advantages of using 
1,2-HOPO over 3,2-HOPO are the lower anion affinity, higher acid resistance of the lanthanide chelate 
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and the utilization of Eu(III) luminescence to reveal information on the solution structure. Further 
research aims on improving the water solubility of 1,2-HOPO derivatives.36 
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Chart 1. 1,2-HOPO, 3,2-HOPO and TAM chelates are used to prepare stable Gd(III) complexes as 
MRI contrast agents.   
 
 
Chart 2. TREN-1,2-HOPO and labeling scheme used to assign the 1H (Figure 4) and 13C NMR spectra. 
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Figure 1. Ortep plot (50 % probability) of [Eu(TREN-1,2-HOPO)(DMF)]2. Non-coordinating solvent 
molecules and hydrogen atoms have been omitted. Selected bond lengths (Å) and angles (deg): Eu1-
O1a 2.389(4); Eu1-O2a 2.387(4); Eu1-O1b 2.360(4); Eu1-O2b 2.366(4); Eu1-O1c 2.407(4); Eu1-O2c 
2.379(4); Eu1-O1s1 2.396(4); Eu1-O3c* 2.467(4); Eu1-O1b-N1b 119.2(3); O1b-N1b-C1b 115.9(5); 
Eu1-O2b-C1b 123.0(4); N1b-C1b-O2b 116.1(5); O1b-Eu1-O2b 64.73(14); Eu1-O3c*-C6c* 125.8(4). 
(*) and (_3) indicate symmetry generated atoms. 
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Figure 2. The emission spectrum of a [Eu(TREN-1,2-HOPO)(H2O)2] in aqueous solution at pH 6. The 
inset shows the expansion of emission spectra in the 5D0 → 7FJ (J = 0, 1; 570 to 600 nm) region and 
corresponding spectral deconvolution into several overlapping Voigt functions. 
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Figure 3. Left: Spectrophotometric titration of TREN-1,2-HOPO. Right: Fitted molar absorbances for 
the five protonation states of TREN-1,2-HOPO. 
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Figure 4. 1H NMR titration of TREN-1,2-HOPO from pH 1.11 to 8.93 in D2O. The labeling scheme is 
depicted in Chart 2. 
* trace of methanol for calibration. 
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Figure 5. Left: Obtained spectra for the competition batch titration of TREN-1,2-HOPO versus DTPA 
for Gd(III) complexation at pH 7.4 in 0.1 M KCl solution. The blue line marks the spectrum of Gd-
TREN-1,2-HOPO, the red line is uncomplexed ligand and between are spectra obtained by addition of 
up to 85 equivalents of DTPA. Right: double logarithmic plot of concentration ratios (at equilibrium; 
after 24 hrs.) for determination of the conditional stability constant pGd7.4 19.3 (2). 
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Figure 6. Comparison of conditional stability constant (pGd) of TREN-1,2-HOPO (blue) with DTPA 
(red) and TREN-3,2-HOPO (green) at variable pH. 
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Figure 7. Left: obtained spectra for the competition batch titration of TREN-1,2-HOPO versus DTPA 
for Zn(II) complexation at pH 7.4 in 0.1 M KCl solution. The blue line marks the spectrum of Zn-
TREN-1,2-HOPO and the red line Zn-TREN-1,2-HOPO with 20 equivalents of DTPA. Right: double 
logarithmic plot of concentration ratios (at equilibrium; after 24 hrs.) for determination of the 
conditional stability constant pZn7.4 15.2 (2). 
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Figure 8. Observed changes in luminescence of a 10 μM solution of [Eu(TREN-1,2-HOPO)] at pH 6 
upon titration with concentrated solutions of several biologically relevant anions. 
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Figure 9. Relaxometric determination of the association constants KA for oxalate (left) and a bidentate 
3,2-HOPO ligand (right) with Gd-TREN-1,2-HOPO (c = 35 µmol; 20 MHz; 25 C).  
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Figure 10. Observed emission spectrum for the oxalate (c = 15 mM) adduct of [Eu(TREN-1,2-
HOPO)(H2O)2] (c = 10 µM) in aqueous solution at pH 6. The inset shows the expansion of emission 
spectra in the 5D0 → 7FJ (J = 0, 1; 570 to 600 nm) region and corresponding spectral deconvolution into 
several overlapping Voigt functions. 
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Scheme 1. Structural changes associated with the deprotonation of TREN-1,2-HOPO. The 
deprotonation of the hydoxylgroups (blue) does not change the hydrogen bonding pattern. The loss of 
hydrogen bonding interaction by removing the proton from the tertiary amine (red) is compensated by 
interaction of the lone pair of the resulting amine with amide protons. 
 
 
Scheme 2. Oxalate binding of Gd-TREN-1,2-HOPO. One oxalate anion bound in a bidentate fashion 
replaces one water molecule increasing the coordination number at Gd(III) from 8 to 9. This illustrates 
the small difference in energy between the eight and nine coordinate geometries. 
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Table 1. Solution thermodynamic constants of TREN-1,2-HOPO. 
 
 logβ pKa 
L3- ? HL2- 7.16 (1) 7.16 (1) 
HL2- ? H2L- 12.78 (2) 5.62 (2) 
H2L
- ? H3L 17.10 (3) 4.32 (3) 
H3L ? H4L+ 20.69 (3) 3.60 (4) 
Gd + L ? GdL 18.5 (2) pGd: 19.3 (2) 
GdL + H ? GdLH 23.5 (2) 5.0 (2) 
GdLH + H ? GdLH2 27.0 (5) 3.5 (5) 
Zn + L ? ZnL 14.4 (2) pZn: 15.2 (2) 
Ca + L ? CaL 8.0 (3) pCa: 8.8 (3) 
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Table 2. Association constants for the formation of the ternary complexes of oxalate and a bidentate 
3,2-HOPO ligand with Ln-TREN-1,2-HOPO (Ln = Gd, Eu). 
 
 
Oxalate 
Relaxometrya
Oxalate 
Luminescence
3,2-HOPO 
Relaxometrya 
logKA (M-1) 1.90 (5) 2.0 3.5 
r1pbound (mM-1 s-1) 5.5 - 5.2 
r1pfree (mM-1 s-1) 9.3 - 9.3 
 
     a) 20 MHz; 25 C 
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a) SYNOPSIS TOC. 
 
Gd-TREN-1,2-HOPO was investigated as a low toxicity and high relaxivity contrast agent for magnetic 
resonance imaging (MRI). Solution thermodynamics address the potential toxicity of Gd-TREN-1,2-
HOPO. TREN-1,2-HOPO is selective for Gd(III) [pGd 19.3 (2)] versus Zn(II) [pZn 15.2 (2)] and Ca(II) 
[pCa 8.8 (3)]. Detailed solution thermodynamic studies applied fluorescence spectroscopy, 
potentiometric, spectrophotometric, NMR and relaxometric titrations. Photophysical measurements of 
the parent luminescent Eu(III) complex reveal insights into the solution structure of this family of 
lanthanide chelates. 
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